Palisade Bio Statistics
Total Valuation
Palisade Bio has a market cap or net worth of $73.39 million. The enterprise value is $61.28 million.
| Market Cap | 73.39M |
| Enterprise Value | 61.28M |
Important Dates
The next estimated earnings date is Friday, May 10, 2024, before market open.
| Earnings Date | May 10, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Palisade Bio has 12.13 million shares outstanding. The number of shares has increased by 677.03% in one year.
| Shares Outstanding | 12.13M |
| Shares Change (YoY) | +677.03% |
| Shares Change (QoQ) | -6.86% |
| Owned by Insiders (%) | 1.75% |
| Owned by Institutions (%) | 15.52% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 293.48 |
| Forward PS | n/a |
| PB Ratio | 6.49 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 245.12 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.15, with a Debt / Equity ratio of 0.03.
| Current Ratio | 5.15 |
| Quick Ratio | n/a |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -820.07 |
Financial Efficiency
Return on equity (ROE) is -89.70% and return on invested capital (ROIC) is -111.88%.
| Return on Equity (ROE) | -89.70% |
| Return on Assets (ROA) | -76.20% |
| Return on Capital (ROIC) | -111.88% |
| Revenue Per Employee | $27,778 |
| Profits Per Employee | -$1.37M |
| Employee Count | 9 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -74.95% in the last 52 weeks. The beta is 1.46, so Palisade Bio's price volatility has been higher than the market average.
| Beta (1Y) | 1.46 |
| 52-Week Price Change | -74.95% |
| 50-Day Moving Average | 5.73 |
| 200-Day Moving Average | 10.25 |
| Relative Strength Index (RSI) | 53.72 |
| Average Volume (30 Days) | 1,076,044 |
Short Selling Information
The latest short interest is 34,516, so 0.28% of the outstanding shares have been sold short.
| Short Interest | 34,516 |
| Short Previous Month | 27,421 |
| Short % of Shares Out | 0.28% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.50 |
Income Statement
In the last 12 months, Palisade Bio had revenue of $250,000 and -$12.32 million in losses. Loss per share was -$27.00.
| Revenue | 250,000 |
| Gross Profit | 250,000 |
| Operating Income | -13.07M |
| Pretax Income | -12.32M |
| Net Income | -12.32M |
| EBITDA | -12.20M |
| EBIT | -12.30M |
| Loss Per Share | -$27.00 |
Balance Sheet
The company has $12.46 million in cash and $369,000 in debt, giving a net cash position of $12.09 million or $1.00 per share.
| Cash & Cash Equivalents | 12.46M |
| Total Debt | 369,000 |
| Net Cash | 12.09M |
| Net Cash Per Share | $1.00 |
| Equity / Book Value | 11.31M |
| Book Value Per Share | 0.93 |
| Working Capital | 10.74M |
Cash Flow
In the last 12 months, operating cash flow was -$11.13 million and capital expenditures -$4,000, giving a free cash flow of -$11.14 million.
| Operating Cash Flow | -11.13M |
| Capital Expenditures | -4,000 |
| Free Cash Flow | -11.14M |
| FCF Per Share | -$24.42 |
Margins
Gross margin is 100.00%, with operating and profit margins of -5,228.00% and -4,926.40%.
| Gross Margin | 100.00% |
| Operating Margin | -5,228.00% |
| Pretax Margin | -4,926.40% |
| Profit Margin | -4,926.40% |
| EBITDA Margin | -4,878.00% |
| EBIT Margin | -4,920.40% |
| FCF Margin | -4,454.80% |
Dividends & Yields
Palisade Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -677.03% |
| Shareholder Yield | -677.03% |
| Earnings Yield | -16.79% |
| FCF Yield | -15.18% |
Analyst Forecast
The average price target for Palisade Bio is $131.25, which is 2,069.42% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $131.25 |
| Price Target Difference | 2,069.42% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -39.87% |
Stock Splits
The last stock split was on April 8, 2024. It was a reverse split with a ratio of 1:15.
| Last Split Date | Apr 8, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
Palisade Bio has an Altman Z-Score of 2.01 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.01 |
| Piotroski F-Score | 3 |